EVOQ Therapeutics Revenue and Competitors
Employee Data
- EVOQ Therapeutics has 9 Employees.
- EVOQ Therapeutics grew their employee count by 0% last year.
EVOQ Therapeutics's People
| Name | Title | Email/Phone |
|---|
EVOQ Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.9M | 12 | 0% | N/A | N/A |
#2 | $2.6M | 34 | -56% | $31.2M | N/A |
#3 | $0.8M | 5 | -44% | N/A | N/A |
#4 | $1.9M | 24 | 100% | N/A | N/A |
#5 | $6M | 39 | -11% | N/A | N/A |
#6 | $4M | 26 | -33% | N/A | N/A |
#7 | $1.9M | 12 | 0% | N/A | N/A |
#8 | $0.8M | 5 | 25% | N/A | N/A |
#9 | $14.6M | 94 | 8% | N/A | N/A |
#10 | $3.4M | 22 | 5% | N/A | N/A |
What Is EVOQ Therapeutics?
EVOQ Therapeutics is developing immunotherapies to improve the lives of individuals fighting autoimmune diseases.\n\nThere are more than 100 chronic autoimmune diseases - many severely debilitating, and some life-threatening. According to the National Institutes of Health, up to 23.5 million Americans (over 7% of the population) suffer from autoimmune disease, and the prevalence is rising.\n\nAutoimmune disease occurs when the body’s central immune tolerance system fails - resulting in T and B cell-mediated destruction of self-tissues. This immune system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis and Rheumatoid Arthritis.\n\nEVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.
keywords:N/A
N/A
Total Funding
9
Number of Employees
N/A
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Ann Arbor
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | 13% | N/A |
#2 | $1.2M | 9 | 0% | N/A |
#3 | $0.7M | 9 | N/A | N/A |
#4 | $1.6M | 9 | -50% | N/A |
#5 | $0.9M | 9 | -36% | N/A |